Malaysiakini
ENBM中文TA
Sign In
Subscribe
  • LifetimeACTIVEINACTIVEEXPIRED
  • Registered on:Renews on:
    ACTIVEINACTIVEEXPIRED
  • Subscribe
  • Renew
  • Extend Subscription
  • Settings
  • Contact Support
  • Sign Out
  • Latest
  • Videos
  • Opinions
  • Yoursay
  • Featured
  • Kini News Lab
  • KiniGuide
  • Sustainability
  • Events
  • Collab Content
  • TopTech
  • Our Team
  • Privacy Policy
  • Terms of Service
  • Advertise with us
  • Careers
  • Email
  • WhatsApp
  • File a complaint
  • Address
Malaysiakini
Subscribe
  • Latest
  • Videos
  • Opinions
  • Yoursay
  • Featured
  • Kini News Lab
  • KiniGuide
  • Sustainability
  • Events
  • Collab Content
  • TopTech
  • Our Team
  • Privacy Policy
  • Terms of Service
  • Advertise with us
  • Careers
  • Email
  • WhatsApp
  • File a complaint
  • Address
ENBM中文TA

      ANNOUNCEMENT

      He was the sole candidate proposed for the post during a state committee meeting.

      He was the sole candidate proposed for the post during a state committee meeting.

      Sinopharm's Covid-19 vaccine 79pct effective, seeks approval in China
      Malaysiakini
      News
      Sinopharm's Covid-19 vaccine 79pct effective, seeks approval in China

      Sinopharm's Covid-19 vaccine 79pct effective, seeks approval in China

      ReutersPublished: Dec 30, 2020 5:35 PM

      An affiliate of China's state-owned drug maker Sinopharm said on Wednesday its Covid-19 vaccine showed 79.34 percent efficacy and it has requested regulatory approval of the shot, moving a step closer to become China's first approved vaccine for general public use.

      The efficacy rate, based on an interim analysis of Phase III clinical trials, is lower than 86 percent rate for the same vaccine announced by the United Arab Emirates on Dec 9, based on preliminary data from trials there...

      Should this be endorsed, it will become China's first approved vaccine for general public use.

      Your guide to Malaysia’s bets in the Covid-19 vaccine race

      Your guide to Malaysia’s bets in the Covid-19 vaccine race

      Singapore begins rollout of Pfizer's Covid-19 vaccine with healthcare workers

      Singapore begins rollout of Pfizer's Covid-19 vaccine with healthcare workers

      Biden offers gloomy vaccine outlook as US reports first case of Covid-19 variant

      Biden offers gloomy vaccine outlook as US reports first case of Covid-19 variant

      Indonesia secures vaccine deals with Pfizer, AstraZeneca

      Indonesia secures vaccine deals with Pfizer, AstraZeneca

      Explaining non-disclosure agreements in Covid-19 vaccine procurement

      Explaining non-disclosure agreements in Covid-19 vaccine procurement

      EU's marathon Covid vaccination drive off to uneven start

      EU's marathon Covid vaccination drive off to uneven start

      Europe rolls out Covid-19 vaccines in bid to leave pandemic behind

      Europe rolls out Covid-19 vaccines in bid to leave pandemic behind

      • comments0
      • facebook
      • whatsapp
      • x
      • comments0
      • facebook
      • whatsapp
      • x
      Related reports7

      Your guide to Malaysia’s bets in the Covid-19 vaccine race

      26-11-2020

      Singapore begins rollout of Pfizer's Covid-19 vaccine with healthcare workers

      30-12-2020

      Biden offers gloomy vaccine outlook as US reports first case of Covid-19 variant

      30-12-2020

      Indonesia secures vaccine deals with Pfizer, AstraZeneca

      29-12-2020

      Explaining non-disclosure agreements in Covid-19 vaccine procurement

      06-01-2021

      EU's marathon Covid vaccination drive off to uneven start

      29-12-2020

      Europe rolls out Covid-19 vaccines in bid to leave pandemic behind

      27-12-2020
      View Comments0

      Comment0

      By posting a comment, you agree to our Commenting Terms and Conditions as stipulated in full here.

      Do's and don'ts when posting comments in Malaysiakini

      TERMS & CONDITIONS

      Foul language, profanity, vulgarity, slanderous, personal attack, threatening, sexually-orientated comments or the use of any method of communication that may violate any law or create needless unpleasantness will not be tolerated. Antisocial behaviour such as "spamming" and "trolling" will be suspended. Violators run the risk of also being blocked permanently.

      REPORT VIOLATORS

      Please use the report feature that is available below each comment to flag offending comments for our moderators to take action. Do not take matters in your own hands to avoid unpleasant and unnecessary exchanges that may result in your own suspension or ban.

      Subscriber-only space:

      Are you a subscriber?

      Sign In

      Not yet a subscriber?

      Subscribe

      600 characters remaining
      mk-logo
      • whatsapp
      • telegram
      • youtube
      • facebook
      • x
      • instagram
      • tiktok
      • linkedin
      • About Us
      • Our Team
      • Privacy Policy
      • Terms of Service
      • Advertise with Us
      • Careers
      • Archive
      • Digital Network
      • KiniTV
      • FG Media
      • RSS Feeds
      • News
      • Opinion
      • Letters
      Contact Editorial
      envelopeeditor@malaysiakini.com
      Contact Subscription/Tech Support
      telephone+6017-323 0707
      envelopesubscribe@malaysiakini.com
      • Advertising
      • advertise@malaysiakini.com
      • advertise@fgmedia.my
      Mkini Dotcom Sdn Bhd
      (199901014818 / 489718-U)No. 9, Jalan 51/205A, Off Jalan Tandang, 46050 Petaling Jaya, Selangor
      Contact Editorial
      envelopeeditor@malaysiakini.com
      Contact Subscription/Tech Support
      telephone+603-7770 0017
      envelopesubscribe@malaysiakini.com
      @Kini
      No. 9, Jalan 51/205A, Off Jalan Tandang, 46050 Petaling Jaya, Selangor